KEYTRUDA® - for Malignant Melanoma
KEYTRUDA® (Pembrolizumab) - for advanced Malignant Melanoma
Monitor closely for immune mediated end organ damage such as Pneumonitis, Colitis, Hepatitis and Nephritis. Continue KEYTRUDA® until disease progression or unacceptable toxicity.
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
KEYTRUDA® (Pembrolizumab) IV 2 mg/kg D1 q21 NSS 250 cc 60 minutes